Recipharm completed the acquisition of Consort Medical for $809m.

Recipharm Group, a Swedish pharmaceutical group, completed the acquisition of Consort Medical, a contract development and pharmaceutical manufacturing company, for $809m. "I am excited at the prospect of combining Recipharm with Consort which is extremely complementary. In our view Bespak is already acknowledged as a leading drug device developer and manufacturer and is a perfect fit for Recipharm's broader pharmaceutical capabilities. The enlarged group will be able to provide finished dose forms in Bespak's key technologies, and provide customers with a far more integrated approach. The Aesica business will further expand our capabilities and capacities in both API and finished dose manufacturing whilst providing access to a new customer base," Thomas Eldered, Recipharm Group CEO.